IKT (Inhibikase Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IKT (Inhibikase Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

IKT

Inhibikase Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Nov 14, 2025
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Aug 19, 2025
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Aug 14, 2025
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
May 14, 2025
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Apr 14, 2025
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
Mar 27, 2025
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Mar 5, 2025
Inhibikase Announces Expansion of Senior Leadership Team
Feb 24, 2025
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Feb 18, 2025
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock
Jan 21, 2025

Reviews